Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | BMEA |
---|---|---|
09:32 ET | 19259 | 10.955 |
09:34 ET | 3800 | 10.82 |
09:36 ET | 2814 | 11.07 |
09:38 ET | 1400 | 11.04 |
09:39 ET | 8521 | 11.22 |
09:41 ET | 4471 | 11.15 |
09:43 ET | 6372 | 11.26 |
09:45 ET | 9364 | 11.185 |
09:48 ET | 5183 | 11.205 |
09:50 ET | 2546 | 11.1 |
09:52 ET | 236 | 11.13 |
09:54 ET | 3475 | 11.0278 |
09:56 ET | 3265 | 11.045 |
09:57 ET | 1400 | 11.08 |
09:59 ET | 400 | 11.13 |
10:01 ET | 1900 | 11.185 |
10:03 ET | 1455 | 11.19 |
10:06 ET | 2946 | 11.14 |
10:08 ET | 2100 | 11.15 |
10:10 ET | 12463 | 11.11 |
10:12 ET | 2727 | 11.12 |
10:14 ET | 1900 | 11.08 |
10:15 ET | 1779 | 11.08 |
10:17 ET | 331 | 11.15 |
10:19 ET | 3003 | 11.21 |
10:21 ET | 3889 | 11.2 |
10:24 ET | 1135 | 11.17 |
10:26 ET | 2900 | 11.1 |
10:28 ET | 3500 | 11.16 |
10:30 ET | 200 | 11.185 |
10:32 ET | 1151 | 11.14 |
10:33 ET | 1505 | 11.11 |
10:35 ET | 401 | 11.105 |
10:37 ET | 817 | 11.12 |
10:39 ET | 1003 | 11.11 |
10:42 ET | 714 | 11.13 |
10:44 ET | 3141 | 11.2 |
10:46 ET | 4848 | 11.05 |
10:48 ET | 12472 | 10.92 |
10:50 ET | 300 | 10.96 |
10:51 ET | 41550 | 11 |
10:53 ET | 800 | 10.95 |
10:55 ET | 450 | 10.95 |
10:57 ET | 900 | 11.08 |
11:00 ET | 800 | 11.05 |
11:02 ET | 2563 | 11.16 |
11:04 ET | 1901 | 11.11 |
11:06 ET | 1900 | 11.15 |
11:08 ET | 3404 | 11.25 |
11:09 ET | 13073 | 11.245 |
11:11 ET | 6015 | 11.33 |
11:13 ET | 4997 | 11.34 |
11:15 ET | 19022 | 11.3 |
11:18 ET | 2813 | 11.21 |
11:20 ET | 2055 | 11.28 |
11:22 ET | 1674 | 11.3 |
11:24 ET | 600 | 11.3 |
11:26 ET | 2245 | 11.21 |
11:27 ET | 100 | 11.145 |
11:29 ET | 2005 | 11.11 |
11:31 ET | 1784 | 11.13 |
11:36 ET | 587 | 11.15 |
11:38 ET | 2572 | 11.09 |
11:40 ET | 2575 | 11.115 |
11:42 ET | 210 | 11.095 |
11:44 ET | 100 | 11.095 |
11:45 ET | 4371 | 11.17 |
11:47 ET | 1907 | 11.15 |
11:49 ET | 190 | 11.155 |
11:51 ET | 700 | 11.125 |
11:54 ET | 1104 | 11.14 |
11:56 ET | 370 | 11.14 |
11:58 ET | 1969 | 11.145 |
12:00 ET | 4435 | 11.115 |
12:02 ET | 450 | 11.11 |
12:03 ET | 100 | 11.11 |
12:05 ET | 200 | 11.11 |
12:07 ET | 1267 | 11.07 |
12:09 ET | 355 | 11.06 |
12:12 ET | 1181 | 11.12 |
12:14 ET | 2038 | 11.05 |
12:16 ET | 3240 | 11.04 |
12:18 ET | 898 | 11.03 |
12:20 ET | 489 | 11.05 |
12:21 ET | 500 | 11.04 |
12:23 ET | 2048 | 11.08 |
12:25 ET | 300 | 11.07 |
12:27 ET | 2359 | 11.03 |
12:30 ET | 3605 | 11.01 |
12:32 ET | 7129 | 10.99 |
12:34 ET | 400 | 10.98 |
12:36 ET | 505 | 10.98 |
12:38 ET | 2650 | 10.95 |
12:39 ET | 11325 | 10.89 |
12:41 ET | 1400 | 10.85 |
12:43 ET | 1398 | 10.83 |
12:45 ET | 904 | 10.8127 |
12:48 ET | 600 | 10.83 |
12:50 ET | 300 | 10.86 |
12:52 ET | 600 | 10.9 |
12:54 ET | 3445 | 10.77 |
12:56 ET | 680 | 10.77 |
12:57 ET | 385 | 10.79 |
12:59 ET | 100 | 10.765 |
01:01 ET | 2300 | 10.75 |
01:03 ET | 1646 | 10.74 |
01:06 ET | 11314 | 10.735 |
01:08 ET | 200 | 10.73 |
01:12 ET | 3862 | 10.64 |
01:14 ET | 3774 | 10.66 |
01:15 ET | 4026 | 10.69 |
01:17 ET | 1500 | 10.7 |
01:19 ET | 100 | 10.69 |
01:21 ET | 3600 | 10.71 |
01:24 ET | 100 | 10.71 |
01:26 ET | 600 | 10.7 |
01:28 ET | 100 | 10.69 |
01:30 ET | 2381 | 10.69 |
01:32 ET | 900 | 10.7 |
01:33 ET | 400 | 10.71 |
01:35 ET | 1850 | 10.7 |
01:37 ET | 2060 | 10.68 |
01:39 ET | 1656 | 10.695 |
01:42 ET | 1167 | 10.72 |
01:44 ET | 100 | 10.73 |
01:46 ET | 420 | 10.72 |
01:48 ET | 200 | 10.73 |
01:50 ET | 10516 | 10.79 |
01:51 ET | 592 | 10.8 |
01:53 ET | 1816 | 10.76 |
01:55 ET | 1477 | 10.78 |
01:57 ET | 750 | 10.77 |
02:00 ET | 478 | 10.76 |
02:02 ET | 470 | 10.76 |
02:06 ET | 2795 | 10.76 |
02:09 ET | 200 | 10.8 |
02:11 ET | 700 | 10.795 |
02:13 ET | 1600 | 10.77 |
02:18 ET | 364 | 10.74 |
02:20 ET | 490 | 10.74 |
02:22 ET | 800 | 10.77 |
02:24 ET | 703 | 10.79 |
02:26 ET | 1337 | 10.7931 |
02:27 ET | 4006 | 10.84 |
02:29 ET | 701 | 10.85 |
02:31 ET | 303 | 10.865 |
02:33 ET | 700 | 10.8607 |
02:36 ET | 2392 | 10.84 |
02:38 ET | 100 | 10.86 |
02:42 ET | 100 | 10.88 |
02:44 ET | 500 | 10.86 |
02:45 ET | 413 | 10.85 |
02:47 ET | 2005 | 10.85 |
02:49 ET | 1029 | 10.875 |
02:51 ET | 169 | 10.86 |
02:54 ET | 100 | 10.86 |
02:56 ET | 1177 | 10.85 |
02:58 ET | 4706 | 10.84 |
03:00 ET | 800 | 10.86 |
03:02 ET | 600 | 10.87 |
03:03 ET | 807 | 10.87 |
03:05 ET | 1000 | 10.86 |
03:07 ET | 400 | 10.87 |
03:09 ET | 200 | 10.87 |
03:12 ET | 1100 | 10.86 |
03:14 ET | 11450 | 10.85 |
03:16 ET | 100 | 10.85 |
03:18 ET | 600 | 10.88 |
03:20 ET | 1895 | 10.89 |
03:21 ET | 700 | 10.95 |
03:23 ET | 2408 | 10.92 |
03:25 ET | 905 | 10.9 |
03:27 ET | 694 | 10.9 |
03:30 ET | 700 | 10.88 |
03:32 ET | 300 | 10.86 |
03:34 ET | 600 | 10.85 |
03:36 ET | 1813 | 10.86 |
03:38 ET | 1607 | 10.81 |
03:39 ET | 4100 | 10.86 |
03:41 ET | 5515 | 10.9 |
03:43 ET | 3813 | 10.85 |
03:45 ET | 900 | 10.81 |
03:48 ET | 2777 | 10.82 |
03:50 ET | 3496 | 10.8492 |
03:52 ET | 4015 | 10.83 |
03:54 ET | 5458 | 10.89 |
03:56 ET | 11180 | 10.9 |
03:57 ET | 9900 | 10.92 |
03:59 ET | 26828 | 10.95 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Biomea Fusion Inc | 378.1M | -3.1x | --- |
enGene Holdings Inc | 387.6M | -1.7x | --- |
Terns Pharmaceuticals Inc | 388.7M | -4.8x | --- |
LENZ Therapeutics Inc | 390.4M | -0.9x | --- |
Aura Biosciences Inc | 364.1M | -3.9x | --- |
Fibrobiologics Inc | 398.5M | -11.0x | --- |
Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The Company is utilizing its proprietary FUSION System to discover, design and develop a pipeline of covalent-binding small molecule medicines designed to maximize clinical benefit for patients. Its lead product candidate, BMF-219, is designed to be an oral, potent, and selective covalent inhibitor of menin, built from its FUSION System. It is developing BMF-219 for the treatment of menin regulated or dependent diseases, such as type 1 and type 2 diabetes as well as subtypes of liquid and solid tumors. Its second development candidate, BMF-500, a covalent inhibitor of activating mutations of the FMS-like tyrosine kinase 3 (FLT3).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $378.1M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 35.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-3.57 |
Book Value | $4.72 |
P/E Ratio | -3.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.